Compugen to Significantly Expand Immuno-Oncology Activitiesin 2014
January 07, 2014 at 09:28 AM EST
Compugen (NASDAQ: CGEN ) announced today that it is significantly increasing its Pipeline Program activities in the field of immuno-oncology. The primary purpose of the increase is to allow research and preclinical activities
